226 related articles for article (PubMed ID: 35259162)
1. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection.
Clark NM; Janaka SK; Hartman W; Stramer S; Goodhue E; Weiss J; Evans DT; Connor JP
PLoS One; 2022; 17(3):e0257930. PubMed ID: 35259162
[TBL] [Abstract][Full Text] [Related]
2. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection.
Clark NM; Janaka SK; Hartman W; Stramer S; Goodhue E; Weiss J; Evans DT; Connor JP
bioRxiv; 2021 Sep; ():. PubMed ID: 34545365
[TBL] [Abstract][Full Text] [Related]
3. Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.
Wendel S; Kutner JM; Machado R; Fontão-Wendel R; Bub C; Fachini R; Yokoyama A; Candelaria G; Sakashita A; Achkar R; Hamerschlak N; Scuracchio P; Amaral M; Dal Ben M; Araujo D; Soares C; Camargo A; Kallás E; Durigon E; Reis LF; Rizzo LV
Transfusion; 2020 Dec; 60(12):2938-2951. PubMed ID: 32935877
[TBL] [Abstract][Full Text] [Related]
4. Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2.
Klingler J; Weiss S; Itri V; Liu X; Oguntuyo KY; Stevens C; Ikegame S; Hung CT; Enyindah-Asonye G; Amanat F; Baine I; Arinsburg S; Bandres JC; Kojic EM; Stoever J; Jurczyszak D; Bermudez-Gonzalez M; Nádas A; Liu S; Lee B; Zolla-Pazner S; Hioe CE
J Infect Dis; 2021 Mar; 223(6):957-970. PubMed ID: 33367897
[TBL] [Abstract][Full Text] [Related]
5. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Neutralizing Antibody Responses towards Full-Length Spike Protein and the Receptor-Binding Domain.
Bayarri-Olmos R; Idorn M; Rosbjerg A; Pérez-Alós L; Hansen CB; Johnsen LB; Helgstrand C; Zosel F; Bjelke JR; Öberg FK; Søgaard M; Paludan SR; Bak-Thomsen T; Jardine JG; Skjoedt MO; Garred P
J Immunol; 2021 Aug; 207(3):878-887. PubMed ID: 34301847
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
8. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
9. Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.
Janaka SK; Clark NM; Evans DT; Mou H; Farzan M; Connor JP
PLoS One; 2021; 16(7):e0253551. PubMed ID: 34310603
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Persistence and Relevant Therapeutic Impact of High-Titer Viral-Neutralizing Antibody in a Convalescent COVID-19 Plasma Super-Donor: A Case Report.
De Rienzo M; Foddai ML; Conti L; Mandoj C; Iaboni S; Saladini I; Castilletti C; Matusali G; Donno DR; Marchioni L; Ianniello S; Corpolongo A; Palange M; Ciliberto G; Piaggio G; De Marco F
Front Immunol; 2021; 12():690322. PubMed ID: 34497602
[TBL] [Abstract][Full Text] [Related]
11. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
Bošnjak B; Stein SC; Willenzon S; Cordes AK; Puppe W; Bernhardt G; Ravens I; Ritter C; Schultze-Florey CR; Gödecke N; Martens J; Kleine-Weber H; Hoffmann M; Cossmann A; Yilmaz M; Pink I; Hoeper MM; Behrens GMN; Pöhlmann S; Blasczyk R; Schulz TF; Förster R
Cell Mol Immunol; 2021 Apr; 18(4):936-944. PubMed ID: 33139905
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection.
Wieczorek L; Zemil M; Merbah M; Dussupt V; Kavusak E; Molnar S; Heller J; Beckman B; Wollen-Roberts S; Peachman KK; Darden JM; Krebs S; Rolland M; Peel SA; Polonis VR
Front Immunol; 2022; 13():901217. PubMed ID: 35711449
[TBL] [Abstract][Full Text] [Related]
14. Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates.
Uzun G; Müller R; Althaus K; Becker M; Marsall P; Junker D; Nowak-Harnau S; Schneiderhan-Marra N; Klüter H; Schrezenmeier H; Bugert P; Bakchoul T
Viruses; 2023 Jun; 15(6):. PubMed ID: 37376656
[TBL] [Abstract][Full Text] [Related]
15. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2.
Gasser R; Cloutier M; Prévost J; Fink C; Ducas É; Ding S; Dussault N; Landry P; Tremblay T; Laforce-Lavoie A; Lewin A; Beaudoin-Bussières G; Laumaea A; Medjahed H; Larochelle C; Richard J; Dekaban GA; Dikeakos JD; Bazin R; Finzi A
Cell Rep; 2021 Mar; 34(9):108790. PubMed ID: 33596407
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
17. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I
J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505
[TBL] [Abstract][Full Text] [Related]
18. Heterologous Ad26/Ad5 adenovirus-vectored vaccines elicited SARS-CoV-2-specific antibody responses with potent Fc activities.
Klingler J; Kowdle S; Bandres JC; Emami-Gorizi R; Alvarez RA; Rao PG; Amanat F; Gleason C; Kleiner G; Simon V; Edelstein A; Perandones C; Upadhyay C; Lee B; Hioe CE
Front Immunol; 2024; 15():1382619. PubMed ID: 38779671
[TBL] [Abstract][Full Text] [Related]
19. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients.
Greenbaum U; Klein K; Martinez F; Song J; Thall PF; Ramdial JL; Knape C; Aung FM; Scroggins J; Knopfelmacher A; Mulanovich V; Borjan J; Adachi J; Muthu M; Leung C; Medina MC; Champlin R; Olson A; Alousi A; Rezvani K; Shpall EJ
Front Immunol; 2021; 12():675679. PubMed ID: 33995420
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand.
Tandhavanant S; Koosakunirand S; Kaewarpai T; Piyaphanee W; Leaungwutiwong P; Luvira V; Chantratita N
PLoS One; 2021; 16(8):e0255796. PubMed ID: 34375345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
